Second-Line Sacituzumab Govitecan Elicits Responses, Provide

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Related Keywords

Ohio , United States , Cleveland , Afshin Dowlati , Roberth Gries , Thoracic Scientific Team At University Hospitals , Jazz Pharmaceuticals , Cancer Drug Development At University Hospitals , Department Of Medicine Division Hematology , School Of Medicine , Gilead Sciences , Astrazeneca , Cleveland Medical Center , Medicine Division , Developmental Therapeutics Program , Case Comprehensive Cancer Center , Endowed Director , Cancer Drug Development , University Hospitals , Thoracic Oncology Program , University Hospitals Seidman Cancer Center , Lung Cancer , Thoracic Scientific Team , Cleveland Medical , Sacituzumab Govitecan , Antibody Drug Conjugate , Trodelvy , Esmo Congress , Tropics 03 Trial , D , Extensive Stage Small Cell Lung Cancer , Es Sclc , Nsclc , Small Cell Lung Cancer ,